Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study).
Giommoni E, Maiello E, Vaccaro V, Rondini E, Vivaldi C, Tortora G, Toppo L, Giordano G, Latiano TP, Lamperini C, Pillozzi S, Boni L, Antonuzzo L, Di Costanzo F. Giommoni E, et al. Among authors: vaccaro v. Curr Oncol. 2021 May 8;28(3):1761-1772. doi: 10.3390/curroncol28030164. Curr Oncol. 2021. PMID: 34066784 Free PMC article. Clinical Trial.
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies.
Loupakis F, Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, Cuppone F, Giannarelli D, Zagonel V, Cognetti F, Tortora G, Falcone A, Bria E. Loupakis F, et al. Among authors: vaccaro v. Cancer. 2012 Mar 15;118(6):1523-32. doi: 10.1002/cncr.26460. Epub 2011 Aug 25. Cancer. 2012. PMID: 22009364 Free article.
Molecular and genetic bases of pancreatic cancer.
Vaccaro V, Gelibter A, Bria E, Iapicca P, Cappello P, Di Modugno F, Pino MS, Nuzzo C, Cognetti F, Novelli F, Nistico P, Milella M. Vaccaro V, et al. Curr Drug Targets. 2012 Jun;13(6):731-43. doi: 10.2174/138945012800564077. Curr Drug Targets. 2012. PMID: 22458519 Free article. Review.
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.
Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, Belli C, Bergamo F, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, Brandi G. Fornaro L, et al. Among authors: vaccaro v. Br J Cancer. 2014 Apr 29;110(9):2165-9. doi: 10.1038/bjc.2014.190. Epub 2014 Apr 8. Br J Cancer. 2014. PMID: 24714745 Free PMC article.
Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.
Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A. Vaccaro V, et al. Biomed Res Int. 2014;2014:351252. doi: 10.1155/2014/351252. Epub 2014 May 4. Biomed Res Int. 2014. PMID: 24877084 Free PMC article. Clinical Trial.
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. Vaccaro V, et al. World J Gastroenterol. 2015 Apr 28;21(16):4788-801. doi: 10.3748/wjg.v21.i16.4788. World J Gastroenterol. 2015. PMID: 25944992 Free PMC article. Review.
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, Bronte V, Scarpa A, Bria E, Tortora G. Carbognin L, et al. Among authors: vaccaro v. PLoS One. 2015 Jun 18;10(6):e0130142. doi: 10.1371/journal.pone.0130142. eCollection 2015. PLoS One. 2015. PMID: 26086854 Free PMC article.
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.
Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, Mosconi S, Vasile E, Santini D, Belli C, Auriemma A, Novarino A, Vaccaro V, Martines C, Marino D, Lutrino SE, Palazzo V, Reinach B, Aldrighetti L, Reni M. Cereda S, et al. Among authors: vaccaro v. Cancer Chemother Pharmacol. 2016 Jan;77(1):109-14. doi: 10.1007/s00280-015-2919-0. Epub 2015 Dec 10. Cancer Chemother Pharmacol. 2016. PMID: 26659366 Clinical Trial.
102 results